Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Advertisement
Advertisement
Trending on Dermatology Times
1
Brepocitinib Clears Skin in 69% of Cutaneous Sarcoidosis Patients
2
Pediatric Atopic Dermatitis: Skin Barrier Care and Early Biologic Use
3
Litifilimab Improves Cutaneous Lupus Symptoms Through 52 Weeks
4
Gene Expression Profiling May Refine Cutaneous Melanoma Care
5